Blueprint Medicines
Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases.
HQ location
Cambridge, United States
Website
Launch date
Employees
Market cap
$8.3b
loading funding rounds…
Nextech Invest(exited)
F-Prime(exited)
Casdin Capital(exited)
Third Rock Ventures(exited)
Eight Roads Ventures(exited)
RA Capital Management(exited)
Perceptive Advisors(exited)
Sixth Street(exited)
Royalty Pharma(exited)
PFM Health Sciences(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (77 %) | 13 % | 22 % | 104 % | 42 % | 33 % | 22 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (352 %) | (259 %) | (189 %) | (30 %) | (9 %) | 10 % | 23 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (358 %) | (273 %) | (203 %) | (13 %) | (6 %) | 8 % | 20 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 334 % | 234 % | 172 % | 67 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Blueprint Medicines
Edit
ACQUISITION by Blueprint Medicines Nov 2021